Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bpi labs llc - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride is indicated for the production of spinal anesthesia for procedures requiring two to three hours. spinal anesthesia with tetracaine hydrochloride is contraindicated in patients with known hypersensitivity to tetracaine hydrochloride or to drugs of a similar chemical configuration (ester-type local anesthetics), or aminobenzoic acid or its derivatives; and in patients for whom spinal anesthesia as a technique is contraindicated. the decision as to whether or not spinal anesthesia should be used for an individual patient should be made by the physician after weighing the advantages with the risks and possible complications. contraindications to spinal anesthesia as a technique can be found in standard reference texts, and usually include generalized septicemia, infection at the site of injection, certain diseases of the cerebrospinal system, uncontrolled hypotension, etc.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hager worldwide, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5), butamben (unii: efw857872q) (butamben - unii:efw857872q), tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - benzocaine 28 mg in .2 g - indications onetouch advanced gel is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. onetouch advanced gel is indicated for use to control pain in the mouth. contraindications onetouch advanced gel is not suitable and should never be used for injection. do not use on the eyes. to avoid excessive systemic absorption, onetouch advanced gel should not be applied to large areas of denuded or inflamed tissue. onetouch advanced gel should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinest-­ erase deficiencies. tolerance may vary with status of the patient.   onetouch advanced gel should not be used under dentures or cotton rolls, as retention of the active gel ingredients under a denture or cotton roll could pos-­ sibly cause an escharotic effect. routine precaution for the use of any topical anesthetic should be observed when using onetouch advanced gel.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hager worldwide, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5), butamben (unii: efw857872q) (butamben - unii:efw857872q), tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - benzocaine 28 mg in .2 g - indications onetouch advanced gel is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. onetouch advanced gel is indicated for use to control pain in the mouth. contraindications onetouch advanced gel is not suitable and should never be used for injection. do not use on the eyes. to avoid excessive systemic absorption, onetouch advanced gel should not be applied to large areas of denuded or inflamed tissue. onetouch advanced gel should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinest-­ erase deficiencies. tolerance may vary with status of the patient.   onetouch advanced gel should not be used under dentures or cotton rolls, as retention of the active gel ingredients under a denture or cotton roll could pos-­ sibly cause an escharotic effect. routine precaution for the use of any topical anesthetic should be observed when using onetouch advanced gel.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hager worldwide, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5), butamben (unii: efw857872q) (butamben - unii:efw857872q), tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - benzocaine 28 mg in .2 g - indications onetouch advanced gel is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. onetouch advanced gel is indicated for use to control pain in the mouth. contraindications onetouch advanced gel is not suitable and should never be used for injection. do not use on the eyes. to avoid excessive systemic absorption, onetouch advanced gel should not be applied to large areas of denuded or inflamed tissue. onetouch advanced gel should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinest-­ erase deficiencies. tolerance may vary with status of the patient.   onetouch advanced gel should not be used under dentures or cotton rolls, as retention of the active gel ingredients under a denture or cotton roll could pos-­ sibly cause an escharotic effect. routine precaution for the use of any topical anesthetic should be observed when using onetouch advanced gel.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

hager worldwide, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5), butamben (unii: efw857872q) (butamben - unii:efw857872q), tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - benzocaine 28 mg in .2 g - indications onetouch advanced gel is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. onetouch advanced gel is indicated for use to control pain in the mouth. contraindications onetouch advanced gel is not suitable and should never be used for injection. do not use on the eyes. to avoid excessive systemic absorption, onetouch advanced gel should not be applied to large areas of denuded or inflamed tissue. onetouch advanced gel should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinest-­ erase deficiencies. tolerance may vary with status of the patient.   onetouch advanced gel should not be used under dentures or cotton rolls, as retention of the active gel ingredients under a denture or cotton roll could pos-­ sibly cause an escharotic effect. routine precaution for the use of any topical anesthetic should be observed when using onetouch advanced gel.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cetylite industries, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5), butamben (unii: efw857872q) (butamben - unii:efw857872q), tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - benzocaine 0.028 g in 0.2 g - cetacaine is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. cetacaine spray is indicated for use to control pain or gagging. cetacaine in all forms is indicated to control pain and for use for surgical or endoscopic or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. it may also be used for vaginal or rectal procedures when feasible. do not use cetacaine spray or cetacaine liquid to treat infants or children younger than 2 years. cetacaine is not suitable and should never be used for injection. do not use on the eyes. to avoid excessive systemic absorption, cetacaine should not be applied to large areas of denuded or inflamed tissue. cetacaine should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. tolerance may vary with the status of the patient. cetacaine should not be used under dentures or cotton rolls, as

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cetylite industries, inc. - benzocaine (unii: u3rsy48jw5) (benzocaine - unii:u3rsy48jw5), butamben (unii: efw857872q) (butamben - unii:efw857872q), tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - benzocaine 0.028 g in 0.2 g - cetacaine topical anesthetic gel is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. cetacaine topical anesthetic gel is indicated for use to control pain and for use for surgical or endoscopic procedures, or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. it may also be used for vaginal or rectal procedures where feasible. do not use cetacaine gel to treat infants or children younger than 2 years. cetacaine is not suitable and should never be used for injection. do not use on the eyes. to avoid excessive systemic absorption, cetacaine topical anesthetic gel should not be applied to large areas of denuded or inflamed tissue. cetacaine topical anesthetic gel should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. tolerance may vary with status of the patient. cetacaine topical anesthetic gel should not be used und

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

terrain pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recomm

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

paragon bioteck, inc. - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride ophthalmic solution usp, 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. tetracaine hydrochloride ophthalmic solution, usp, 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution usp, 0.5% in pregnant women. animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution usp, 0.5% is excreted in human milk or to assess its effects on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution usp, 0.5% and any potential adverse effects on the breastfed child from tetracaine hydro

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

oceanside pharmaceuticals - tetracaine hydrochloride (unii: 5nf5d4opci) (tetracaine - unii:0619f35cgv) - tetracaine hydrochloride ophthalmic solution, usp 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. tetracaine hydrochloride ophthalmic solution, usp 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. risk summary there are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, usp 0.5% in pregnant women. animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. risk summary there are no data to assess whether tetracaine hydrochloride ophthalmic solution, usp 0.5% is excreted in human milk or to assess its effects on milk production/excretion. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tetracaine hydrochloride ophthalmic solution, usp 0.5% and any potential adverse effects on the breastfed child from tetracaine hydroc